Cargando…

Diagnostic impact of CEA and CA 15-3 on chemotherapy monitoring of breast cancer patients

INTRODUCTION: Serum tumor markers have emerged as an effective tool to determine prognosis and treatment efficiency in different cancer types. This study aimed to explore the chemotherapy monitoring efficiency and prognostic sensitivity of tumor-associated cancer antigen 15-3 (CA 15-3) and carcinoem...

Descripción completa

Detalles Bibliográficos
Autor principal:	Hasan, Diya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AboutScience 2022
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9644433/ https://www.ncbi.nlm.nih.gov/pubmed/36381348 http://dx.doi.org/10.33393/jcb.2022.2446

Ejemplares similares

Serum CEA and CA 15-3 as prognostic factors in primary breast cancer
por: Ebeling, F G, et al.
Publicado: (2002)

Primary Cutaneous Mucinous Carcinoma Monitoring: A Role for CA15.3 and CEA?
por: Ginguay, Antonin, et al.
Publicado: (2022)

Diagnostic Utility of Combined CEA, CA15-3 and CA125 Biomarkers and Cytomorphology in Suspicious and Malignant Serosal Fluid
por: Rahemi, Zahra, et al.
Publicado: (2021)

Use of CEA and CA15-3 to Predict Axillary Lymph Node Metastasis in Patients with Breast Cancer
por: Wu, San-Gang, et al.
Publicado: (2016)

Concordance of Hypermethylated DNA and the Tumor Markers CA 15-3, CEA, and TPA in Serum during Monitoring of Patients with Advanced Breast Cancer
por: Kristiansen, Søren, et al.
Publicado: (2015)

Association of Preoperative Serum Levels of CEA and CA15-3 with Molecular Subtypes of Breast Cancer
por: Zhao, Wenjing, et al.
Publicado: (2021)

Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases
por: Nicolini, Andrea, et al.
Publicado: (2006)

Clinical utility of tumour marker velocity of cancer antigen 15–3 (CA 15–3) and carcinoembryonic antigen (CEA) in breast cancer surveillance
por: Hing, J.X., et al.
Publicado: (2020)

Prognostic value of monitoring tumour markers CA 15-3 and CEA during fulvestrant treatment
por: Bartsch, Rupert, et al.
Publicado: (2006)

Nipple Discharge of CA15-3, CA125, CEA and TSGF as a New Biomarker Panel for Breast Cancer
por: Wang, Gangping, et al.
Publicado: (2014)

Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients.
por: Nicolini, A., et al.
Publicado: (1991)

FTO, PIK3CB serve as potential markers to complement CEA and CA15-3 for the diagnosis of breast cancer
por: Mi, Jintao, et al.
Publicado: (2023)

The prognostic role of variations in tumour markers (CEA, CA15.3) in patients with metastatic breast cancer treated with CDK4/6 inhibitors
por: Sottotetti, Federico, et al.
Publicado: (2022)

Combined Evaluation of AFP, CA15-3, CA125, CA19-9, and CEA Tumor Markers in Patients with Hepatitis B and C
por: ASSMAR, Mehdi, et al.
Publicado: (2016)

Diagnostic and Prognostic Value of CEA and CA19-9 in Colorectal Cancer
por: Lakemeyer, Leilani, et al.
Publicado: (2021)

Assessing Clinical Significance of Serum CA15-3 and Carcinoembryonic Antigen (CEA) Levels in Breast Cancer Patients: A Meta-Analysis
por: Fu, Yijie, et al.
Publicado: (2016)

Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer
por: Shao, Yingbo, et al.
Publicado: (2015)

Improved sensitivity for detection of breast cancer by combination of miR-34a and tumor markers CA 15-3 or CEA
por: Zaleski, Martin, et al.
Publicado: (2018)

Enhancement of diagnostic performance in lung cancers by combining CEA and CA125 with autoantibodies detection
por: Zang, Ruochuan, et al.
Publicado: (2019)

Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy
por: Sun, Zhipeng, et al.
Publicado: (2014)

Thioredoxin 1 as a serum marker for breast cancer and its use in combination with CEA or CA15-3 for improving the sensitivity of breast cancer diagnoses
por: Park, Byung-Joon, et al.
Publicado: (2014)

Dual-Channel Detection of Breast Cancer Biomarkers CA15-3 and CEA in Human Serum Using Dialysis-Silicon Nanowire Field Effect Transistor
por: Li, Hang, et al.
Publicado: (2022)

Prognostic Impact of Elevation of Cancer Antigen 15-3 (CA15-3) in Patients With Early Breast Cancer With Normal Serum CA15-3 Level
por: Ryu, Jai Min, et al.
Publicado: (2023)

The use of tumour markers CEA, CA-195 and CA-242 in evaluating the response to chemotherapy in patients with advanced colorectal cancer.
por: Ward, U., et al.
Publicado: (1993)

The dynamic monitoring of CEA in response to chemotherapy and prognosis of mCRC patients
por: Yu, Ping, et al.
Publicado: (2018)

Diagnostic and prognostic value of CEA, CA19–9, AFP and CA125 for early gastric cancer
por: Feng, Fan, et al.
Publicado: (2017)

An individual reference limit of the serum CEA–TPA–CA 15-3 tumor marker panel in the surveillance of asymptomatic women following surgery for primary breast cancer
por: Nicolini, Andrea, et al.
Publicado: (2018)

Nomograms for Predicting the Prognostic Value of Pre-Therapeutic CA15-3 and CEA Serum Levels in TNBC Patients
por: Dai, Danian, et al.
Publicado: (2016)

Combined detection of CA15-3, CEA, and SF in serum and tissue of canine mammary gland tumor patients
por: Fan, Yuying, et al.
Publicado: (2021)

Clinical significance and diagnostic value of serum CEA, CA19-9 and CA72-4 in patients with gastric cancer
por: Liang, Yao, et al.
Publicado: (2016)

Prognostic Values Of Preoperative Serum CEA And CA125 Levels And Nomograms For Young Breast Cancer Patients
por: Li, Xuan, et al.
Publicado: (2019)

An updated evaluation of serum sHER2, CA15.3, and CEA levels as biomarkers for the response of patients with metastatic breast cancer to trastuzumab-based therapies
por: Perrier, Alexandre, et al.
Publicado: (2020)

Monitoring the treatment outcome in endometrial cancer patients by CEA and TATI
por: Kozakiewicz, Barbara, et al.
Publicado: (2016)

Menstrual Cycle Dependent Variability for Serum Tumor Markers CEA, AFP, CA 19-9, CA 125 and CA 15-3 in Healthy Women
por: Erbağci, Ayşe Binnur, et al.
Publicado: (1999)

Sensitivity of Symptomatology Versus Diagnostic Procedures and Concentration of CEA and CA19–9 in the Early Detection of Colorectal Cancer
por: Vukobrat-Bijedic, Zora, et al.
Publicado: (2014)

Clinical significance and diagnostic value of serum NSE, CEA, CA19-9, CA125 and CA242 levels in colorectal cancer
por: Luo, Hai, et al.
Publicado: (2020)

Combined measurement of CA 15-3 with novel autoantibodies improves diagnostic accuracy for breast cancer
por: Dong, Xuejun, et al.
Publicado: (2013)

Carbon Nanopowder-Based Stochastic Sensor for Ultrasensitive Assay of CA 15-3, CEA and HER2 in Whole Blood
por: Stefan-van Staden, Raluca-Ioana, et al.
Publicado: (2022)

Preoperative serum levels of CEA and CA 242 in colorectal cancer.
por: Carpelan-Holmström, M., et al.
Publicado: (1995)

Prognostic value of CEA and CA19-9 in patients with local advanced rectal cancer receiving neoadjuvant chemoradiotherapy, radical surgery and postoperative chemotherapy
por: Shan, Jingjing, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jpvruuguj2377egvjbaf6hj8ct